Get Ready | Diabetes on the Net

For healthcare professionals only

In association with the

For prescribing information UKIE

Improving cardiovascular outcomes in type 2 diabetes with SGLT2 inhibitors – What is the role of the cardiologist?

Please sign in below:

The next event will begin in:

Days
Hours
Minutes
Seconds

The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional webcast, including speaker honoraria and presentation development support where applicable. Boehringer Ingelheim andLilly Diabetes Alliance products will be discussed in this webcast.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 3281627 (freephone)

Adverse events should be reported. Reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue 
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 2913960 Fax: +44 1344 742661
or by email: PV_local_UK_Ireland@boehringer-ingelheim.com
*

Defined as new patients prescribed JARDIANCE, patients switched to JARDIANCE from another type 2 diabetes treatment or JARDIANCE added to another type 2 diabetes treatment

Reference
1. Data on File. IQVIA new patient opportunity data April 2019. Boehringer Ingelheim.
2. Jardiance Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/28973 (accessed June 2020)

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.